Monitoring Monoclonal Antibody Delivery in Oncology: The Example of Bevacizumab

Developing therapeutic monoclonal antibodies paves the way for new strategies in oncology using targeted therapy which should improve specificity. However, due to a lack of biomarkers, a personalized therapy scheme cannot always be applied with monoclonal antibodies. As a consequence, the efficacy o...

Descripción completa

Detalles Bibliográficos
Autores principales: Nugue, Guillaume, Bidart, Marie, Arlotto, Marie, Mousseau, Mireille, Berger, François, Pelletier, Laurent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3741214/
https://www.ncbi.nlm.nih.gov/pubmed/23951280
http://dx.doi.org/10.1371/journal.pone.0072021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3741214/
https://www.ncbi.nlm.nih.gov/pubmed/23951280
http://dx.doi.org/10.1371/journal.pone.0072021

Ejemplares similares